- Home
- GLUE vs RES Comparison
GLUE vs RES Comparison
Compare GLUE & RES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLUE | RES |
|---|---|---|
| Founded | 2019 | 1984 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | GLUE | RES |
|---|---|---|
| Price | $19.06 | $6.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $29.50 | $5.44 |
| AVG Volume (30 Days) | 972.4K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.16 |
| Revenue | $75,622,000.00 | ★ $41,919,000,000.00 |
| Revenue This Year | $84.02 | $6.48 |
| Revenue Next Year | N/A | $7.04 |
| P/E Ratio | $72.42 | ★ $37.38 |
| Revenue Growth | N/A | ★ 2216.21 |
| 52 Week Low | $3.50 | $4.10 |
| 52 Week High | $25.77 | $6.85 |
Technical Indicators
Market Signals| Indicator | GLUE | RES |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 53.76 |
| Support Level | $17.79 | $5.49 |
| Resistance Level | $19.24 | $5.89 |
| Average True Range (ATR) | 1.25 | 0.30 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 35.41 | 57.71 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About RES RPC Inc.
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. The company's operating segment includes Technical Services and Support Services. It generates maximum revenue from the Technical Services segment. Technical Services segment nclude RPC's oil and gas services that utilize people and equipment to perform value-added completion, production and maintenance services directly to a customer's well. Support Services segment consists of drill pipe and related tools, pipe handling, pipe inspection and storage services, and oilfield training and consulting services.